Skip to main content
Clinical Trials/NCT06104267
NCT06104267
Recruiting
Not Applicable

A Single-Arm, Prospective, Exploratory Study to Evaluate Feasibility and Effect of Medical Tai Chi Exercise Healing in Treating mCRC Patients

The First Affiliated Hospital with Nanjing Medical University1 site in 1 country30 target enrollmentSeptember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment
30
Locations
1
Primary Endpoint
Adherence rates
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

As a traditional martial art in China, Tai Chi Chuan has excellent health benefits along with its combat function.Studies have shown that Tai Chi as an exercise prescription can significantly reduce the incidence of cancer, but the complexity of Tai Chi Chuan routines, poor disease targeting, and the lack of traditional internal mental and physical training method limit the healing of tumours and other diseases. For this reason, we have established the Medical Tai Chi Exercise Healing System(MTCEH), which integrates Tai Chi exercise, traditional Chinese internal mental and physical training method, rehabilitation medicine and sports medicine methods, on the basis of evidence-based medicine and with the aim of targeting different tumour treatments. With the characteristics of easily learning, internal and external training, and individualised treatment of tumours, this series of routines effectively combines traditional oriental Tai Chi martial arts with tumour treatment, which opens up a beautiful and mysterious oriental healing journey for integrative medicine.

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Histological or cytological documentation of adenocarcinoma of the colon or rectum.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
  • Life expectancy of at least 6 months.
  • Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratory required by protocol(ALT/AST≤2.5×UNL or ≤5×UNL with liver metastasis,TBIL≤2.5×UNL,Cr≤1.5×UNL,WBC≥3×109/L,NE≥1.5×109/L,PLT≥80×109/L,Hb≥90g/L,PT-INR/APTT \<1.5UNL; LVEF≥ 50%).
  • Subjects must complete the treatment and follow-up on schedule according to the research plan.

Exclusion Criteria

  • Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)\].
  • Any serious or unstable medical condition、mental illness or known active alcohol or drug abuse or dependence.
  • Unhealed surgical wounds and intolerance
  • Extreme fatigue, anemia (\<80 g/L) or dystaxia
  • toxicity grade ≥III in chemoradiotherapy or targeted therapy (NCI-CTCAE 5.0), or severe intolerance
  • exercise contraindications for patients with cardiovascular diseases or pulmonary diseases (referring to the Chinese Guideline for Cardiac Rehabilitation and Secondary Prevention \[edition 2018\] and Evidence-based Practice Guidelines for Clinical Rehabilitation of Chronic obstructive Pulmonary Disease \[edition 2021\]); uncontrolled unstable angina, diastolic dysfunction grade IV, uncontrolled severe arrhythmia, uncontrolled hypertension;
  • high fever, serious infection, dyscrasia, multiple organ failure, or incapability to cooperate
  • thrombosis in the active phase
  • For female subjects: they should be surgical sterilized, postmenopausal patients, or agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period; The serum or urine pregnancy test must be negative within 7 days before enrollment and must be non lactating. Male subjects: patients who agree to use a medically approved contraceptive method during the study treatment period and within 6 months after the end of the study treatment period.
  • other conditions confirmed by the multidisciplinary cancer rehabilitation team.

Outcomes

Primary Outcomes

Adherence rates

Time Frame: post 8-week intervention

The adherence rates will be measured by the number of tai chi sessions performed divided by the total possible tai chi sessions

Secondary Outcomes

  • self-rating anxiety scale(SAS)(post 8-week intervention)
  • the Pittsburgh Sleep Quality Index (PSQI)(post 8-week intervention)
  • EORTC - Quality of Life(post 8-week intervention)
  • the Brief Fatigue Inventory (BFI)(post 8-week intervention)
  • self-rating depression scale(SDS)(post 8-week intervention)

Study Sites (1)

Loading locations...

Similar Trials